Disclosure Summary
As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity.  Safeguards against commercial bias have been put in place.  Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.  Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Relevant financial relationship(s) with industry:

None

No relevant financial relationship(s) with industry:

Barbara L. Baasch Thomas
Andrew D. Badley, M.D.
Elie F. Berbari, M.D.
Jen Curran
Gregory J. Gores, M.D.
Mitchell R. Humphreys, M.D.
Michael J. Joyner, M.D.

Reference to off-label usage(s) of pharmaceuticals or instruments in their presentation:

Andrew D. Badley, M.D.        
Hydroxychloroquine, HIV protease inhibitors, MMPD, Remdesivir,  Plasma, Lenzilumab, Tocilizumab Sarilumab, Ecilizumab, Ravulizumab, Losartan

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.